Indoco Remedies rises on getting EIR from USFDA for API manufacturing facility at Patalganga [Healthcare]
AI Summary1 min read
TL;DR
Indoco Remedies has received an Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Patalganga, enhancing its global pharmaceutical operations and growth prospects.
Tags
Pharmaceuticals & DrugsHealthcare
Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company caters to both domestic and International markets. Indoco has strengthened its wings in the international markets and offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide. The company has a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs). Expertise in Research & Development, backward integration in API in select products, own CRO set-up, excellence in Finished Dosages manufacturing and a strong customer base will ensure consistent growth in the Company’s Domestic, as well as International business.